


HASTANEDE GELİŞEN PNÖMONİLER



Dr. Buket Ertürk Şengel
Marmara Üniversitesi Pendik Eğitim ve Araştırma
Hastanesi
Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji ABD

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

Andre C. Kalil,^{1,a} Mark L. Metersky,^{2,a} Michael Klompas,^{3,4} John Muscedere,⁵ Daniel A. Sweeney,⁶ Lucy B. Palmer,⁷ Lena M. Napolitano,⁸ Naomi P. O'Grady,⁹ John G. Bartlett,¹⁰ Jordi Carratalà,¹¹ Ali A. El Solh,¹² Santiago Ewig,¹³ Paul D. Fey,¹⁴ Thomas M. File Jr,¹⁵ Marcos I. Restrepo,¹⁶ Jason A. Roberts,^{17,18} Grant W. Waterer,¹⁹ Peggy Cruse,²⁰ Shandra L. Knight,²⁰ and Jan L. Brozek²¹

¹Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha; ²Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington; ³Brigham and Women's Hospital and Harvard Medical School, and ⁴Harvard Pilgrim Health Care Institute, Boston, Massachusetts; ⁵Department of Medicine, Critical Care Program, Queens University, Kingston, Ontario, Canada; ⁶Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego; ⁷Department of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, State University of New York at Stony Brook; ⁸Department of Surgery, Division of Trauma, Critical Care and Emergency Surgery, University of Michigan, Ann Arbor; ⁹Department of Critical Care Medicine, National Institutes of Health, Bethesda, and ¹⁰Johns Hopkins University School of Medicine, Baltimore, Maryland; ¹¹Department of Infectious Diseases, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, Spanish Network for Research in Infectious Diseases, University of Barcelona, Spain; ¹²Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo, Veterans Affairs Western New York Healthcare System, New York; ¹³Thoraxzentrum Ruhrgebiet, Department of Respiratory and Infectious Diseases, EVK Herne and Augusta-Kranken-Anstalt Bochum, Germany; ¹⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha; ¹⁵Summa Health System, Akron, Ohio; ¹⁶Department of Medicine, Division of Pulmonary and Critical Care Medicine, South Texas Veterans Health Care System and University of Texas Health Science Center at San Antonio; ¹⁷Burns, Trauma and Critical Care Research Centre, The University of Queensland, ¹⁸Royal Brisbane and Women's Hospital, Queensland, and ¹⁹School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; ²⁰Library and Knowledge Services, National Jewish Health, Denver, Colorado; and ²¹Department of Clinical Epidemiology and Biostatistics and Department of Medicine, McMaster University, Hamilton, Ontario, Canada



KLİMİK

TÜRK KLİNİK MİKROBİYOLOJİ VE
İNFEKSİYON HASTALIKLARI DERNEĞİ

Türk Klinik Mikrobiyoloji ve
İnfeksiyon Hastalıkları Derneği



Türkiye Enfeksiyon Hastalıkları ve
Klinik Mikrobiyoloji Uzmanlık Derneği

TÜRK TORAKS DERNEĞİ ERİŞKİNLERDE HASTANEDE GELİŞEN PNÖMONİ TANİ VE TEDAVİ UZLAŞI RAPORU 2018



Klinik Mikrobiyoloji Uzmanlık Derneği

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia

Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT)

Antoni Torres^{1,16}, Michael S. Niederman^{2,16}, Jean Chastre³, Santiago Ewig⁴, Patricia Fernandez-Vandellos⁵, Hakan Hanberger⁶, Marin Kollef⁷, Gianluigi Li Bassi¹, Carlos M. Luna⁸, Ignacio Martin-Loeches⁹, J. Artur Paiva¹⁰, Robert C. Read¹¹, David Rigau¹², Jean François Timsit¹³, Tobias Welte¹⁴ and Richard Wunderink¹⁵

Tanımlar

■ Hastanede Gelişen Pnömoni (HGP);

- Hastaneye *yatıştan 48 saat sonra* gelişen ve yatışında inkübasyon döneminde olmadığı bilinen pnömoni
- Hastaneden *taburcu olduktan sonra 48 saat içinde* ortaya çıkan pnömoni

Tanımlar

■ Ventilatörle İlişkili Pnömoni (ViP)

- *Entübasyon sırasında pnömonisi olmayan, invazif MV desteğindeki hastada **entübasyondan 48 saat sonra** gelişen pnömoni*

■ Ventilatörle İlişkili Trakeobronşit (ViTB):

- 48-72 saattir MV'e bağlı hastada akciğer **grafisinde infiltrasyon olmaksızın** başka nedene bağlı olmayan,
 - >38°C ateş
 - Pürülan balgam
 - Lökositoz ya da lökopeni kriterlerinden **ikisinin** olması

HGP tanı, tedavi ve izleminde...

Göğüs hastalıkları

Enfeksiyon hastalıkları ve klinik mikrobiyoloji

Radyoloji

Yoğun bakım

Mikrobiyoloji uzmanları ve

Hastane enfeksiyon kontrol komitesi



Multidisipliner
yaklaşım gerekir

HGP, ViP: bu tanımların amacı ne?

- **Dirençli ya da çoğul ilaç dirençli bakterilerle** enfeksiyon riski olan hastaları belirlemek
- Ancak
- Bu sınıflamalar duyarlı olmakla birlikte **gereksiz geniş spektrum antibiyotik kullanımına** yol açtığı da unutulmamalıdır
- **2016 IDSA rehberinde;**
 - *Sağlık bakım ilişkili pnömoninin (SBİP) çoğul ilaç direnci taşıyan patojenler açısından yüksek risk taşımadığı !*

- Multidrug resistant (MDR) (Çok ilaca dirençli, ÇİD):
 - *Üç veya daha fazla antibiyotik sınıfından en az birer antibiyotiğe direnç* olması
- Extensively drug resistant (XDR) (Aşırı ilaç direnci):
 - *1-2 sınıf hariç hemen tüm antibiyotik sınıflarında en az bir antibiyotiğe direnç* vardır
- Pandrug resistant (PDR):
 - *Tüm antibiyotik sınıflarına direnç* olması

HGP genel bilgiler

- Hastanede yatan hastalarda %0.2 - 2
- **Hastane enfeksiyonları içerisinde %15 – 22**
- Hastanede gelişen enfeksiyonlar içinde **en sık ölüm nedeni**
- Hastaneye yatışın ilk 48 saatinde, hastanın üst solunum yolları florası hastanedeki dirençli bakteriler ile yer değiştirmeye başlar ve
- **Yatıştan 48 saat sonra** hastane florası ile kolonizasyon oranları belirgin olarak artar

■ Çok ilaca dirençli (ÇİD) olmayan bakteriler

- *S.pneumoniae*, *H.influenzae*, *Enterobacteriaceae* (*E.coli*, *Klebsiella*, *Proteus* ve *Serratia* spp), Metisiline duyarlı *Staphylococcus aureus* (MSSA), *Legionella pneumophila*

■ Çok ilaca dirençli (ÇİD) bakteriler

- *Pseudomonas aeruginosa*
- *E.coli* ve diğer *Enterobacteriaceae*
(GSBL ve/veya karbapenemaz üreten)
- *Klebsiella pneumoniae*
(GSBL, karbapenemaz üreten)
- *Acinetobacter* spp
- *Stenotrophomonas maltophilia*
- Metisiline dirençli *Staphylococcus aureus* (**MRSA**)**

HGP/VİP tanısı: klinik kriterler

- Yeni gelişen akciğer infiltrasyonu + ve bunun enfeksiyöz orijinli olduğunu destekleyen bulgular (2/3)
 - 1. Ateş
 - 2. Lökositoz
 - 3. Pürülan sekresyon
- Solunum örneği kültürü
 - *ETA $\geq 10^5$ cfu/ml (non-kantitatif)*
 - *BAL $\geq 10^4$ cfu/ml (kantitatif)*
 - *Bronkoskopik korunmuş fırça $\geq 10^3$ cfu/ml (kantitatif)*
- (CPIS) (Klinik pulmoner enfeksiyon skoru)
 - *>6 olması pnömoniye destekler*

Klinik Kriter

Duyarlılık %60-70

Özgüllük %75


Klinik pulmoner enfeksiyon skoru (CPIS)

Kriter	Skor
Ateş ≥38.5 ama ≤38.9 >39 veya <36	1 2
Lökositoz <4,000 veya > 11,000/μL Çomak > 50%	1 1 (ek olarak)
Oksijenizasyon PaO ₂ / FiO ₂ > 250 ve ARDS yok	2
Akciğer grafisi Lokalize infiltrat Yamalı veya diffüz infiltrat İnfiltratların ilerlemesi (ARDS veya kalp yetmezliği yok)	2 1 2
Trakeal aspirat Orta - yüksek yoğunlukta üreme Üreyen izolat morfolojisi direk incelemede de var	1 1 (ek olarak)
Maksimum skor 12: tanı anında infiltratta ilerleme ve kültür sonucu olmadığından başlangıçta maksimum skor 8-10 olur.	


Duyarlılık ve özgüllüğü %65 civarında

- 70 yaşında kadın hasta bir haftadır **kontROLSÜZ diyabet** nedeni ile dahiliye servisinde takip edilirken **ateş, üşüme titreme** gelişmesi nedeni ile değerlendiriliyor.
- Öyküsünde son 3 ayda hastane yatışı ya da intravenöz antibiyotik kullanımı yok. Son iki gündür **hafif öksürük** tarifliyor, balgam çıkarmıyor.
- Fizik muayenede **ateşi 38.4 °C**, tansiyonu: 130/80 mmHg, solunum sayısı 20/dk, nabızı 90/dk. Solunum muayenesinde **sol akciğer orta - alt bölgelerde krepitan raller** duyuluyor.
- Hemogramında **lökosit sayısı 17.000/mm³**, %80 PMNL
- **CRP 130 mg/L**
- **Prokalsitonin (PCT) 12 ng/L**
- Kreatinin, ALT ve AST normal sınırlarda

A



B



İki set periferik kan kültürü alınıyor

■ Bu hastada en uygun ampirik antibiyotik tedavi seçeneği aşağıdakilerden hangisidir?

- A. Seftriakson
- B. Seftriakson + siprofloksasin
- C. Sefepim veya piperasilin tazobaktam monoterapi
- D. Pip/tazo + siprofloksasin
- E. Pip/Tazo + siprofloksasin + vankomisin
- F. Sefepim + linezolid

Table 4. Recommended Initial Empiric Antibiotic Therapy for Hospital-Acquired Pneumonia (Non-Ventilator-Associated Pneumonia)

Not at High Risk of Mortality ^a and no Factors Increasing the Likelihood of MRSA ^{b,c}	Not at High Risk of Mortality ^a but With Factors Increasing the Likelihood of MRSA ^{b,c}	High Risk of Mortality or Receipt of Intravenous Antibiotics During the Prior 90 d ^{a,c}
One of the following:	One of the following:	Two of the following, avoid 2 β -lactams:
Piperacillin-tazobactam ^d 4.5 g IV q6h	Piperacillin-tazobactam ^d 4.5 g IV q6h	Piperacillin-tazobactam ^d 4.5 g IV q6h
OR	OR	OR
Cefepime ^d 2 g IV q8h	Cefepime ^d or ceftazidime ^d 2 g IV q8h	Cefepime ^d or ceftazidime ^d 2 g IV q8h
OR	OR	OR
Levofloxacin 750 mg IV daily	Levofloxacin 750 mg IV daily	Levofloxacin 750 mg IV daily
	Ciprofloxacin 400 mg IV q8h	Ciprofloxacin 400 mg IV q8h
	OR	OR
Imipenem ^d 500 mg IV q6h	Imipenem ^d 500 mg IV q6h	Imipenem ^d 500 mg IV q6h
Meropenem ^d 1 g IV q8h	Meropenem ^d 1 g IV q8h	Meropenem ^d 1 g IV q8h
	OR	OR
	Aztreonam 2 g IV q8h	Amikacin 15–20 mg/kg IV daily
		Gentamicin 5–7 mg/kg IV daily
		Tobramycin 5–7 mg/kg IV daily
		OR
		Aztreonam ^e 2 g IV q8h
	Plus:	Plus:
	Vancomycin 15 mg/kg IV q8–12h with goal to target 15–20 mg/mL trough level (consider a loading dose of 25–30 mg/kg $\times$ 1 for severe illness)	Vancomycin 15 mg/kg IV q8–12h with goal to target 15–20 mg/mL trough level (consider a loading dose of 25–30 mg/kg IV $\times$ 1 for severe illness)
	OR	OR
	Linezolid 600 mg IV q12h	Linezolid 600 mg IV q12h
		If MRSA coverage is not going to be used, include coverage for MSSA. Options include: Piperacillin-tazobactam, cefepime, levofloxacin, imipenem, meropenem. Oxacillin, nafcillin, and cefazolin are preferred for the treatment of proven MSSA, but would ordinarily not be used in an empiric regimen for HAP.
		If patient has severe penicillin allergy and aztreonam is going to be used instead of any β -lactam-based antibiotic, include coverage for MSSA.

HGP mortalite ve ÇİD risk faktörleri

Mortaliteyi artıran risk faktörleri

- Ventilatör tedavisi gerektiren HGP
- Septik şok

ÇİD Pseudomonas ve diğer gram negatif basil ve MRSA risk faktörü

- IV antibiyotik kullanım öyküsü – son 90 gün içerisinde

ÇİD Pseudomonas ve diğer gram negatif basil enfeksiyonu risk faktörü

- Yapısal akciğer hastalığı (kistik fibroz, bronşektazi)
- Solunum örneğinde yoğun gram negatif bakteri varlığı
- Daha önceden gram negatif enfeksiyon veya kolonizasyon olması

MRSA risk faktörleri

- Ünite de S aureus izolatlarının >%20 metisilin dirençli olması
- Ünite de MRSA sıklığı bilinmiyorsa
- Hasta MRSA ile kolonize ise

Table 4. Recommended Initial Empi

Not at High Risk of Mortality^a and no
Factors Increasing the Likelihood of
MRSA^{b,c}

One of the following:

Piperacillin-tazobactam^d 4.5 g IV q6h

OR

Cefepime^d 2 g IV q8h

OR

Levofloxacin 750 mg IV daily

Imipenem^d 500 mg IV q6h

Meropenem^d 1 g IV q8h

Mortalite risk faktörü yok

MRSA risk faktörü yok

Not at High Risk of Mortality^a but With Factors
Increasing the Likelihood of MRSA^{b,c}

One of the following:

Piperacillin-tazobactam^d 4.5 g IV q6h

OR

Cefepime^d or ceftazidime^d 2 g IV q8h

OR

Levofloxacin 750 mg IV daily

Ciprofloxacin 400 mg IV q8h

OR

Imipenem^d 500 mg IV q6h

Meropenem^d 1 g IV q8h

OR

Aztreonam 2 g IV q8h

Plus:

Vancomycin 15 mg/kg IV q8–12h with goal to target
15–20 mg/mL trough level (consider a loading
dose of 25–30 mg/kg × 1 for severe illness)

OR

Linezolid 600 mg IV q12h

Mortalite risk faktörü yok

MRSA risk faktörü **var**

High Risk of Mortality or Receipt of Intravenous Antibiotics During the Prior 90 d^{a,c}

Two of the following, avoid 2 β -lactams:

Piperacillin-tazobactam^d 4.5 g IV q6h

OR

Cefepime^d or ceftazidime^d 2 g IV q8h

OR

Levofloxacin 750 mg IV daily

Ciprofloxacin 400 mg IV q8h

OR

Imipenem^d 500 mg IV q6h

Meropenem^d 1 g IV q8h

OR

Amikacin 15–20 mg/kg IV daily

Gentamicin 5–7 mg/kg IV daily

Tobramycin 5–7 mg/kg IV daily

OR

Aztreonam^e 2 g IV q8h

Plus:

Vancomycin 15 mg/kg IV q8–12h with goal to target 15–20 mg/mL trough level (consider a loading dose of 25–30 mg/kg IV $\times$ 1 for severe illness)

OR

Linezolid 600 mg IV q12h

If MRSA coverage is not going to be used, include coverage for MSSA.

Options include:

Piperacillin-tazobactam, cefepime, levofloxacin, imipenem, meropenem. Oxacillin, nafcillin, and cefazolin are preferred for the treatment of proven MSSA, but would ordinarily not be used in an empiric regimen for HAP.

Mortalite risk faktörü **var**

Veya

Son 90 günde IV antibiyotik kullanımı **var**

Çok ilaca
dirençli
Pseudomonas,
Acinetobacter
ve diğer gram
negatif'lerin
etken olduğu
HGP için
risk faktörleri

- Ağır altta yatan hastalık varlığı
- Önceki 90 gün içinde IV antibiyotik kullanımı
- Geniş spektrumlu antibiyotik kullanımı
- Yapısal akciğer hastalığı
(bronşektazi, kistik fibrozis)
- Kortikosteroid tedavi
- Gram negatif izolatların en az %10'unun monoterapiye dirençli olduğu bir ünite de tedavi*
- Solunum sekresyonu gram boyamasında çok sayıda ve predominant gram negatif basil*

Legionella için risk faktörleri

- Hastaneden kullanılan su hazneleri
- Önceden hastane kökenli Legionellozis öyküsü

Anaeroblar için risk faktörleri

- Gingivit veya periodontal hastalık
- Yutma bozukluğu
- Bilinçte bozulma
- Orotrakeal girişim

MRSA'nın etken olduğu **HGP/VİP** için risk faktörleri

- Önceki 90 gün içinde İV antibiyotik kullanımı

*MRSA ülkemizde nadir görülen bir HGP/VİP nedenidir. Özellikle önceden kolonize olan hastalarda ve prevelansı yüksek ünitelerde takip edilen hastalarda düşünülmelidir [5,32,48].

Hastada HGP/VAP tedavisinin başlanmasında **klirik kriterler yeterli mi** yoksa klinik kriterlerin yanında PCT'de kullanılmalı mı?

IV. In Patients With Suspected HAP/VAP, Should Procalcitonin (PCT) Plus Clinical Criteria or Clinical Criteria Alone Be Used to Decide Whether or Not to Initiate Antibiotic Therapy?

Recommendation

1. For patients with suspected HAP/VAP, we recommend using **clinical criteria alone**, rather than using serum PCT plus clinical criteria, to decide whether or not to initiate antibiotic therapy (*strong recommendation, moderate-quality evidence*).

- Tedavi başlanmasında **CRP**'nin de klinik kriterler üzerine ekstra etkisi YOK

VI. In Patients With Suspected HAP/VAP, Should C-Reactive Protein (CRP) Plus Clinical Criteria, or Clinical Criteria Alone, Be Used to Decide Whether or Not to Initiate Antibiotic Therapy?

Recommendation

1. For patients with suspected HAP/VAP, we recommend using clinical criteria alone rather than using CRP plus clinical criteria, to decide whether or not to initiate antibiotic therapy (*weak recommendation, low-quality evidence*).

- Tedavi başlanmasında **CPIS skorunun** da klinik kriterler üzerine ekstra etkisi YOK

VII. In Patients With Suspected HAP/VAP, Should the Modified Clinical Pulmonary Infection Score (CPIS) Plus Clinical Criteria, or Clinical Criteria Alone, Be Used to Decide Whether or Not to Initiate Antibiotic Therapy?

Recommendation

1. For patients with suspected HAP/VAP, we suggest using clinical criteria alone, rather than using CPIS plus clinical criteria, to decide whether or not to initiate antibiotic therapy (*weak recommendation, low-quality evidence*).

- Ampirik tedavi verilen HGP hastasında MRSA riski olmasa da MSSA (metisilin duyarlı *S.aureus*) kapsanmalıdır?

1. For patients being treated empirically for HAP, we recommend prescribing an antibiotic with activity against *S. aureus* (*strong recommendation, very low-quality evidence*). (See below for recommendations regarding empiric coverage of MRSA vs MSSA.)
 - i. For patients with HAP who are being treated empirically and have either a risk factor for MRSA infection (ie, prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of *S. aureus* isolates are methicillin resistant, or the prevalence of MRSA is not known, or who are at high risk for mortality, we suggest prescribing an

- Ampirik tedavi verilen HGP hastasında *Pseudomonas aeruginosa* ve diğer gram negatifler kapsanmalıdır?

2. For patients with HAP who are being treated empirically, we recommend prescribing antibiotics with activity against *P. aeruginosa* and other gram-negative bacilli (*strong recommendation, very low-quality evidence*).

- i. For patients with HAP who are being treated empirically and have factors increasing the likelihood for *Pseudomonas* or other gram-negative infection (ie, prior intravenous antibiotic use within 90 days; also see Remarks) or a high risk for mortality, we suggest prescribing antibiotics from 2 different classes with activity against *P. aeruginosa* (*weak recommendation, very low-quality evidence*). (Risk factors for mortality include need for ventilatory support due to HAP and septic shock). All other patients with HAP who are being treated empirically may be prescribed a single antibiotic with activity against *P. aeruginosa*.

Çok ilaca
dirençli
Pseudomonas,
Acinetobacter
ve diğer gram
negatif'lerin
etken olduğu
HGP için
risk faktörleri

- Ağır altta yatan hastalık varlığı
- Önceki 90 gün içinde IV antibiyotik kullanımı
- Geniş spektrumlu antibiyotik kullanımı
- Yapısal akciğer hastalığı (bronşektazi, kistik fibrozis)
- Kortikosteroid tedavi
- Gram negatif izolatların en az %10'unun monoterapiye dirençli olduğu bir ünite de tedavi*
- Solunum sekresyonu gram boyamasında çok sayıda ve predominant gram negatif basil*

- **Pseudomonas aeruginosa üredi:** ikili vs tekli antipseudomonal? (duyarlılık biliniyor)
- **Septik şok veya artmış mortalite riski varsa:** ikili tx

XVII. Should Monotherapy or Combination Therapy Be Used to Treat Patients With HAP/VAP Due to *P. aeruginosa*?

Recommendations

1. For patients with HAP/VAP due to *P. aeruginosa* who are **not** in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy (*strong recommendation, low-quality evidence*).
2. For patients with HAP/VAP due to *P. aeruginosa* who remain in septic shock or at a high risk for death when the results of antibiotic susceptibility testing are known, we suggest combination therapy using 2 antibiotics to which the isolate is susceptible rather than monotherapy (*weak recommendation, very low-quality evidence*).

□ Optimal tedavi süresi 7 gün

XXII. What Is the Optimal Duration of Antibiotic Therapy for HAP (Non-VAP)?

Recommendation

1. For patients with HAP, we recommend a 7-day course of antimicrobial therapy (*strong recommendation, very low-quality evidence*).

Remarks: There exist situations in which a shorter or longer duration of antibiotics may be indicated, depending upon the rate of improvement of clinical, radiologic, and laboratory parameters.

Hastanede gelişen pnömonide etken **MRSA** ise, önerilen optimal antibiyotik tedavi süresi **14 gündür**. Benzer şekilde ***Pseudomonas aeruginosa***, ***Acinetobacter baumannii*** ve ***Stenotrophomonas spp.*** gibi **nonfermentatif bakterilerin** neden olduğu HGP'li hastalarda da tedavi süresi 14 güne uzatılabilir (**TTD uzlaşısı raporu**)

- Antibiyotik kesilmesinde **klirik kriterler + PCT** kullanılması öneriliyor

XXIV. Should Discontinuation of Antibiotic Therapy Be Based Upon PCT Levels Plus Clinical Criteria or Clinical Criteria Alone in Patients With HAP/VAP?

Recommendation

1. For patients with HAP/VAP, we suggest using PCT levels plus clinical criteria to guide the discontinuation of antibiotic therapy, rather than clinical criteria alone (*weak recommendation, low-quality evidence*).

Remarks: It is not known if the benefits of using PCT levels to determine whether or not to discontinue antibiotic therapy exist in settings where standard antimicrobial therapy for VAP is already 7 days or less.

Başlangıç PCT değerinin > %80 düşmesi ya da < 0.5 ng/L olması antibiyotik kesilmesi konusunda yol göstericidir

- 75 yaşında kadın hasta serebrovasküler olay nedeni ile yaklaşık **3 gündür entübe olarak MV desteği altında** yoğun bakım ünitesinde takip ediliyor.
- Hastanın son 2 **gündür sekresyonlarında artış** ve **oksijen ihtiyacında artışla** birlikte **38.8 °C ateşi** oluyor, tansiyonu 115/75 mmHg.
- Öyküde son 3 ayda hastane yatışı, IV antibiyotik yok.
- AC-PA grafi: **sağ alt zonda yeni gelişen infiltrasyon**
- Hemogram **lökosit sayısı: 11.500/mm³**
- CRP son 3 gün 70 → 180 → 290 mg/L
- **Prokalsitonin 4 ng/L**
- DTA ve periferik kan kültürleri alınıyor

Table 3. Suggested Empiric Treatment Options for Clinically Suspected Ventilator-Associated Pneumonia in Units Where Empiric Methicillin-Resistant *Staphylococcus aureus* Coverage and Double Antipseudomonal/Gram-Negative Coverage Are Appropriate

A. Gram-Positive Antibiotics With MRSA Activity	+	B. Gram-Negative Antibiotics With Antipseudomonal Activity: β -Lactam-Based Agents	+	C. Gram-Negative Antibiotics With Antipseudomonal Activity: Non- β -Lactam-Based Agents
Glycopeptides ^a Vancomycin 15 mg/kg IV q8–12h (consider a loading dose of 25–30 mg/kg $\times$ 1 for severe illness)		Antipseudomonal penicillins ^b Piperacillin-tazobactam 4.5 g IV q6h ^b		Fluoroquinolones Ciprofloxacin 400 mg IV q8h Levofloxacin 750 mg IV q24h
OR		OR		OR
Oxazolidinones Linezolid 600 mg IV q12h		Cephalosporins ^b Cefepime 2 g IV q8h Ceftazidime 2 g IV q8h		Aminoglycosides ^{a,c} Amikacin 15–20 mg/kg IV q24h Gentamicin 5–7 mg/kg IV q24h Tobramycin 5–7 mg/kg IV q24h
		OR		OR
		Carbapenems ^b Imipenem 500 mg IV q6h ^d Meropenem 1 g IV q8h		Polymyxins ^{a,e} Colistin 5 mg/kg IV $\times$ 1 (loading dose) followed by 2.5 mg $\times$ (1.5 $\times$ CrCl + 30) IV q12h (maintenance dose) [135] Polymyxin B 2.5–3.0 mg/kg/d divided in 2 daily IV doses
		OR		
		Monobactams ^f Aztreonam 2 g IV q8h		

Table 3. Suggested Empiric Treatment of *Staphylococcus aureus* Coverage:

A. Gram-Positive Antibiotics With MRSA Activity

Glycopeptides^a

Vancomycin 15 mg/kg IV q8–12h
(consider a loading dose of 25–30 mg/kg x 1 for severe illness)

OR

Oxazolidinones

Linezolid 600 mg IV q12h

B. Gram-Negative Antibiotics With
Antipseudomonal Activity: β -Lactam-Based Agents

Antipseudomonal penicillins^b

Piperacillin-tazobactam 4.5 g IV q6h^b

OR

Cephalosporins^b

Cefepime 2 g IV q8h

Ceftazidime 2 g IV q8h

OR

Carbapenems^b

Imipenem 500 mg IV q6h^d

Meropenem 1 g IV q8h

OR

Monobactams^f

Aztreonam 2 g IV q8h

C. Gram-Negative Antibiotics With Antipseudomonal Activity: Non- β -Lactam-Based Agents

Fluoroquinolones

Ciprofloxacin 400 mg IV q8h

Levofloxacin 750 mg IV q24h

OR

Aminoglycosides^{a,c}

Amikacin 15–20 mg/kg IV q24h

Gentamicin 5–7 mg/kg IV q24h

Tobramycin 5–7 mg/kg IV q24h

OR

Polymyxins^{a,e}

Colistin 5 mg/kg IV $\times$ 1 (loading dose) followed by 2.5 mg $\times$ (1.5 $\times$ CrCl + 30) IV q12h (maintenance dose) [135]

Polymyxin B 2.5–3.0 mg/kg/d divided in 2 daily IV doses

VİP - ÇİD risk faktörleri

(1) ÇİD risk faktörleri (Pseudomonas, diğer gr (-) basiller ve MRSA)

- Son 90 gün içerisinde İV antibiyotik kullanımı
- Septik şok (VİP ile birlikte)
- VİP öncesi ARDS olması
- VİP öncesi ≥ 5 gün hastane yatışı
- VİP öncesi akut renal replasman tedavisi uygulanması

A + B + C

(2) ÇİD Pseudomonas ve diğer gram negatif basiller için risk faktörü

- YBÜ 'deki gram negatiflerde monoterapide kullanılacak ajana $> \%10$ direnç olması
- ÇİD Pseudomonas ve diğer gram negatiflerle kolonize olması
- YBÜ deki direnç paterninin bilinmemesi

(3) MRSA risk faktörü

- Ünitedeki *S. aureus* izolatlarının $>\% 20$ metisilin dirençli olması
- MRSA ile kolonizasyon olması
- Ünite MRSA sıklığının bilinmemesi

- IDSA – ATS VİP ampirik tedavi önerileri
- *S.aureus* (MSSA), *Pseudomonas aeruginosa* ve diğer gram negatifler tüm ampirik rejimlerde kapsanıyor olmalı
- **MRSA** risk faktörü varsa (tablo, madde 3) vankomisin veya linezolid
- **ÇİD riski varsa ikili anti-pseudomonal ajan** kullanılmalı (tablo, madde 1 veya 2)
- Üreyen etkene karşı etkili alternatif tedavi ajanları mevcutsa **aminoglikozit ve polimiksin grubundan kaçınılmalı**
- *Pseudomonas aeruginosa* direnç oranı <%10 ve başka direnç riski yoksa **monoterapi** kullanılabilir.
- **Tedavi süresi 7 gün** (MRSA ve non-fermenter gram negatiflerde klinik ve lab bulgularına göre uzatılabilir)

MICROBIOLOGIC METHODS TO DIAGNOSE VAP AND HAP

I. Should Patients With Suspected VAP Be Treated Based on the Results of Invasive Sampling (ie, Bronchoscopy, Blind Bronchial Sampling) With Quantitative Culture Results, Noninvasive Sampling (ie, Endotracheal Aspiration) With Quantitative Culture Results, or Noninvasive Sampling With Semiquantitative Culture Results?

Recommendation

1. We suggest noninvasive sampling with semiquantitative cultures to diagnose VAP, rather than invasive sampling with quantitative cultures and rather than noninvasive sampling with quantitative cultures (*weak recommendation, low-quality evidence*).

Remarks: Invasive respiratory sampling includes bronchoscopic techniques (ie, bronchoalveolar lavage [BAL], protected specimen brush [PSB]) and blind bronchial sampling (ie, mini-BAL). Noninvasive respiratory sampling refers to endotracheal aspiration.

ROLE OF INHALED ANTIBIOTIC THERAPY

XIV. Should Patients With VAP Due to Gram-Negative Bacilli Be Treated With a Combination of Inhaled and Systemic Antibiotics, or Systemic Antibiotics Alone?

Recommendation

1. For patients with VAP due to gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins (colistin or polymyxin B), we suggest both inhaled and systemic antibiotics, rather than systemic antibiotics alone (*weak recommendation, very low-quality evidence*).

XIX. Which Antibiotic Should Be Used to Treat Patients With HAP/VAP Due to *Acinetobacter* Species?

Recommendations

1. In patients with HAP/VAP caused by *Acinetobacter* species, we suggest treatment with either a carbapenem or ampicillin/sulbactam if the isolate is susceptible to these agents (*weak recommendation, low-quality evidence*).
2. In patients with HAP/VAP caused by *Acinetobacter* species that is sensitive only to polymyxins, we recommend intravenous polymyxin (colistin or polymyxin B) (*strong recommendation, low-quality evidence*), and we suggest adjunctive inhaled colistin (*weak recommendation, low-quality evidence*).

XX. Which Antibiotic Should Be Used to Treat Patients With HAP/VAP Due to Carbapenem-Resistant Pathogens?

Recommendation

1. In patients with HAP/VAP caused by a carbapenem-resistant pathogen that is sensitive only to polymyxins, we recommend intravenous polymyxins (colistin or polymyxin B) (*strong recommendation, moderate-quality evidence*), and we suggest adjunctive inhaled colistin (*weak recommendation, low-quality evidence*).

- Hastaya **Piperasilin / Tazobaktam** (4x4.5 gram)
+ **siprofloksasin** (2x400mg) başlandı
- Ateş yanıtı alındı
- CRP ve PCT yavaş da olsa düşme eğiliminde
- Oksijen ihtiyacı henüz azalmadı
- DTA Üreme: 10^6 cfu/ml *Pseudomonas aeruginosa*,
 - *Meropenem* **duyarlı**
 - *İmipenem* **orta duyarlı**
 - *Siprofloksasin* **orta duyarlı**
 - *Sefepim* **orta duyarlı**
 - *Piperasilin tazobaktam* **orta duyarlı**
 - *Seftazidim* **orta duyarlı**

European Committee on Antimicrobial Susceptibility Testing

Breakpoint tables for interpretation of MICs and zone diameters

Version 14.0, valid from 2024-01-01

This document should be cited as "The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. <http://www.eucast.org>."

Content	Page	Additional information
Changes	1	
Notes	4	
Guidance on reading EUCAST Breakpoint Tables	6	
Dosages used to define breakpoints	7	
Information on technical uncertainty	11	
Enterobacterales	13	
Pseudomonas spp.	20	
Stenotrophomonas maltophilia	25	Link to Guidance Document on Stenotrophomonas maltophilia
Acinetobacter spp.	27	
Staphylococcus spp.	32	
Enterococcus spp.	39	
Streptococcus groups A, B, C and G	44	
Streptococcus pneumoniae	49	
Viridans group streptococci	55	
Haemophilus influenzae	60	
Moraxella catarrhalis	66	
Neisseria gonorrhoeae	70	
Neisseria meningitidis	74	
Anaerobic bacteria	78	
Helicobacter pylori	82	
Listeria monocytogenes	83	
Pasteurella spp.	85	
Campylobacter jejuni and C. coli	87	
Corynebacterium spp. other than C. diphtheriae and C. ulcerans	88	
Corynebacterium diphtheriae and C. ulcerans	90	
Aerococcus sanguinicola and A. urinae	92	
Kingella kingae	94	
Aeromonas spp.	96	
Achromobacter xylosoxidans	98	
Vibrio spp.	99	
Bacillus spp. (except Bacillus anthracis)	101	

S (susceptible) standart ilaç dozunda duyarlı

I (orta duyarlı) demek değil

I – yüksek dozda ilaç maruziyetinde duyarlı

European Committee on Antimicrobial Susceptibility Testing

Breakpoint tables for interpretation of MICs and zone diameters

Version 14.0, valid from 2024-01-01

Notes

1. The EUCAST clinical breakpoint tables contain clinical MIC breakpoints (determined or revised during 2002-2023) and their inhibition zone diameter correlates. The EUCAST breakpoint tables version 14.0 includes corrected typographical errors, clarifications, breakpoints for new agents and/or organisms, revised MIC breakpoints and revised and new zone diameter breakpoints. Changes are best seen on screen or on a colour printout since cells containing a change are yellow. New or revised comments are underlined. Removed comments are shown in strikethrough font style.

2. PK-PD (Non-species related) breakpoints are listed separately.

3. Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method.

4. Antimicrobial agent names in blue are linked to EUCAST rationale documents. MIC and zone diameter breakpoints in blue are linked to the search page of the EUCAST MIC and zone diameter distribution database.

5. The document is released as an Excel file suitable for viewing on screen and as an Acrobat pdf file suitable for printing. To utilize all functions in the Excel file, use Microsoft original programs only. The Excel file enables users to alter the list of agents to suit the local range of agents tested. The content of single cells cannot be changed. Hide lines by right-clicking on the line number and choose "hide". Hide columns by right-clicking on the column letter and choose "hide".

6. EUCAST breakpoints are used to categorise results into three susceptibility categories:

S - Susceptible, standard dosing regimen: A microorganism is categorised as *Susceptible, standard dosing regimen*, when there is a high likelihood of therapeutic success using a

I - Susceptible, increased exposure: A microorganism is categorised as *Susceptible, increased exposure** when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection.

*Exposure is a function of how the mode of administration, dose, dosing interval, infusion time, as well as distribution and excretion of the antimicrobial agent will influence the infecting organism at the site of infection.

7. Dash in breakpoint tables indicates that the agent is unsuitable for treatment of infections caused by the organism or group of organisms and that testing and clinical use should be avoided. If included, report resistant without prior testing.

8. "IE" indicates that there is insufficient evidence that the organism or group is a good target for therapy with the agent. An MIC with a comment but without an accompanying S, I or R categorisation may be reported.

9. A screening test uses one agent to predict resistance or susceptibility to one or more antimicrobial agents in the same class. The screening test is often more sensitive and/or robust than testing individual agents. Using a screening test will often reduce the number of tests needed in primary susceptibility testing since it will predict susceptibility and/or resistance to several agents. Guidance on how to act on the screening test result is described in the Note related to each specific screening test.

Negative screening test: MIC below or equal to or zone diameter above or equal to the susceptible breakpoint for the screening agent. No resistance mechanisms to the antimicrobial class detected.

Positive screening test: MIC above or zone diameter below the resistant breakpoint for the screening agent. Resistance mechanisms to the antimicrobial class detected.

Fluoroquinolones	Standard dosage	High dosage
Ciprofloxacin	0.5 g x 2 oral or 0.4 g x 2 iv	0.75 g x 2 oral or 0.4 g x 3 iv
Delafloxacin	0.45 g x 2 oral or 0.3 g x 2 iv	None
Levofloxacin	0.5 g x 1 oral or 0.5 g x 1 iv	0.5 g x 2 oral or 0.5 g x 2 iv
Moxifloxacin	0.4 g x 1 oral or 0.4 g x 1 iv	None
Norfloxacin	None	None
Ofloxacin	0.2 g x 2 oral or 0.2 g x 2 iv	0.4 g x 2 oral or 0.4 g x 2 iv

Ceftazidime	1 g x 3 iv	2 g x 3 iv or 1 g x 6 iv
Ceftazidime-avibactam	(2 g ceftazidime + 0.5 g avibactam) x 3 iv over 2 hours	
Ceftibuten	0.4 g x 1 oral	None
Ceftobiprole	0.5 g x 3 iv over 2 hours	None
Ceftolozane-tazobactam (intra-abdominal infections and UTI)	(1 g ceftolozane + 0.5 g tazobactam) x 3 iv over 1 hour	None
Ceftolozane-tazobactam (hospital acquired pneumonia, including ventilator associated pneumonia)	(2 g ceftolozane + 1 g tazobactam) x 3 iv over 1 hour	None
Ceftriaxone	2 g x 1 iv	2 g x 2 iv or 4 g x 1 iv
Cefuroxime iv	0.75 g x 2 iv	1.5 g x 2 iv

		by extended 3-hour infusion
Piperacillin-tazobactam	(4 g piperacillin + 0.5 g tazobactam) x 4 iv or x 3 by extended 4-hour infusion	(4 g piperacillin + 0.5 g tazobactam) x 4 iv by extended 3-hour infusion



TEŞEKKÜR EDERİM